Figure 2.

Average pre-meal capillary blood glucose levels from Subject 2 over the 4 days before (blue circles) and 9 days after (red squares) the addition of empagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor.

Data is mean ± SEM.